23andMe Holding Co.
Change company Symbol lookup
Select an option...
ME 23andMe Holding Co.
DIS Walt Disney Co
BONTQ Bon-Ton Stores Inc
DDS Dillard's Inc
BALTF iPath? Bloomberg Cotton Subindex Total Return(SM) ETN
SBLK Star Bulk Carriers Corp
NTAP NetApp Inc
ABMD ABIOMED Inc
CHK Chesapeake Energy Corp
BNFT Benefitfocus Inc
Go

Company profile

23andMe Holding Co., formerly VG Acquisition Corp., is a consumer genetics and research company. The Company offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The Company operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.

Postmarket

Last Trade
Delayed
$2.82
0.02 (0.71%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$2.80
Day's Change
-0.15 (-5.08%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
2.95
Day's Low
2.74
Volume
(Light)
Volume:
2,323,199

10-day average volume:
2,968,854
2,323,199

Display:

Providers:

UpdateCancel
6 providers
May 12, 2022
23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results

EQNX::TICKER_START (NASDAQ:ME), EQNX::TICKER_END 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter...(Globe Newswire)

March 15, 2022
23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and therapeutics company with a mission to help people access, understand, and benefit from the human genome, today announced that it will present data related to its wholly...(Globe Newswire)

February 25, 2022
23andMe to Present at Cowen 42nd Annual Health Care Conference

23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Cowen 42nd...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.